Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials
Liver International · 2026-01 · 46 (1)
DOI: 10.1111/liv.70489 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Liver International, online erschienen am 22.12.2025. Verfasst von Elias D Rady und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA. Hauptthemen laut MEDLINE: Glycerophospholipids, Alcohol Drinking, Fatty Liver. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, National Institute on Alcohol Abuse and Alcoholism, American Association for the Study of Liver Diseases.
Abstract (Originalsprache)
Accurate quantification of alcohol intake is essential for the diagnosis, subclassification, and management of steatotic liver disease (SLD). In everyday clinical practice, alcohol histories rely primarily on physician‐assisted self‐report, with validated questionnaires used variably. Both provider‐level inconsistencies in documentation and patient‐level factors (e.g., recall and social‐desirability biases) can contribute to misclassification of SLD subtypes. Phosphatidylethanol (PEth), a direct alcohol biomarker detectable for ~2–4 weeks, has emerged as a promising objective tool that can complement self‐report. Across diverse SLD populations, PEth consistently uncovers underreported alcohol use, sharpens subclassification, informs prognosis, and enables longitudinal monitoring to guide care. In liver transplantation, PEth supports documentation of abstinence and detection of relapse to enable timely intervention. This mini‐review synthesises current evidence on PEth in SLD, emphasises its value in both clinical and research settings, and outlines priorities for integrating PEth into structured care pathways and clinical trial design to improve outcomes and harmonise endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Digestive and Liver Diseases, UT Southwestern Medical Center, Dallas, Texas, USA.
- Evidentis Clinical Research, Fort Worth, Texas, USA.
ORCID-Profile: Elias D Rady, Thomas G Cotter
Förderung
- NIAAA NIH HHS
- National Institute on Alcohol Abuse and Alcoholism
- American Association for the Study of Liver Diseases
Zitieren
APA
Rady, E. D., & Cotter, T. G. (2026). Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials. Liver International, 46(1). https://doi.org/10.1111/liv.70489
Vancouver
Rady ED, Cotter TG. Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials. Liver International. 2026;46(1). doi:10.1111/liv.70489
BibTeX
@article{Rady2026,
author = {Rady, Elias D and Cotter, Thomas G},
title = {Integrating Phosphatidylethanol to Enhance Alcohol Quantification in Steatotic Liver Disease and Clinical Trials},
journal = {Liver International},
year = {2026},
volume = {46},
number = {1},
doi = {10.1111/liv.70489}
}
EUVIMED